Illumina, Kohl’s, Arrowhead, TAI Diagnostics, & More
Summary
The drug candidate was developed to treat hepatitis B. Arrowhead is also seeking the green light to add trial sites in Hong Kong and South Korea.Arrowhead received FDA approval in April to start a Phase 2b trial of ARC-520 in the U.S., but at a lower dosage than the company initially proposed.The retailer spent $75 million turning the 300,000-square-foot building into an open, collaborative space for hundreds of employees in IT, store design, purchasing, and supply chain operations, the Milwaukee Journal Sentinel reported.The company now occupies 40,000 square feet and employs around 70 people in Madison, a number that could grow to 90 by the end of the year, a spokeswoman told Xconomy.—The Commons, which helps Milwaukee-area university students form startups or work on research and development projects for local corporations, has moved into the Ward 4 co-working space owned and operated by Milwaukee venture fund CSA Partners.
